Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
56.65
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
873
Open
56.65
Bid (Size)
56.74 (5)
Ask (Size)
56.77 (22)
Prev. Close
56.65
Today's Range
56.65 - 56.65
52wk Range
42.64 - 58.97
Shares Outstanding
1,250,690,553
Dividend Yield
3.36%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Performance
YTD
+13.30%
+13.30%
1 Month
+0.68%
+0.68%
3 Month
+17.21%
+17.21%
6 Month
+14.35%
+14.35%
1 Year
+4.54%
+4.54%
More News
Read More
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Via
Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Via
MarketBeat
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
September 23, 2024
Via
Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
September 23, 2024
Via
Benzinga
Exposures
Product Safety
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
September 20, 2024
Via
Benzinga
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
September 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
Via
Benzinga
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
Via
The Motley Fool
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
Via
MarketBeat
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Via
Benzinga
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Despite its impressive fundamentals, NASDAQ:SNY remains undervalued.
September 10, 2024
Via
Chartmill
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
Via
Benzinga
Exposures
Product Safety
Why Sanofi Stock Was Robustly Healthy Today
September 03, 2024
Via
The Motley Fool
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
September 03, 2024
Via
Benzinga
European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday?
September 02, 2024
Via
Benzinga
Topics
Energy
Exposures
Fossil Fuels
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
Via
Benzinga
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
August 24, 2024
Via
The Motley Fool
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
August 20, 2024
Via
Benzinga
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
August 19, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.